These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33859749)

  • 61. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
    Yilmaz D; Tuzer M; Unlu MB
    Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
    Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
    Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations.
    Bailleul Q; Navarin P; Arcicasa M; Bal-Mahieu C; Carcaboso AM; Le Bourhis X; Furlan A; Meignan S; Leblond P
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918823
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302.
    Wojtkowiak JW; Cornnell HC; Matsumoto S; Saito K; Takakusagi Y; Dutta P; Kim M; Zhang X; Leos R; Bailey KM; Martinez G; Lloyd MC; Weber C; Mitchell JB; Lynch RM; Baker AF; Gatenby RA; Rejniak KA; Hart C; Krishna MC; Gillies RJ
    Cancer Metab; 2015; 3(1):2. PubMed ID: 25635223
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.
    Voissiere A; Jouberton E; Maubert E; Degoul F; Peyrode C; Chezal JM; Miot-Noirault É
    PLoS One; 2017; 12(7):e0181340. PubMed ID: 28704566
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
    Badar T; Handisides DR; Benito JM; Richie MA; Borthakur G; Jabbour E; Harutyunyan K; Konoplev S; Faderl S; Kroll S; Andreeff M; Pearce T; Kantarjian HM; Cortes JE; Thomas DA; Konopleva M
    Am J Hematol; 2016 Aug; 91(8):800-5. PubMed ID: 27169385
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts.
    Hagtvet E; Røe K; Olsen DR
    Radiat Oncol; 2011 Oct; 6():135. PubMed ID: 21981945
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.
    Kumar S; Sun JD; Zhang L; Mokhtari RB; Wu B; Meng F; Liu Q; Bhupathi D; Wang Y; Yeger H; Hart C; Baruchel S
    Transl Oncol; 2018 Aug; 11(4):911-919. PubMed ID: 29803017
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In Vivo Identification of Adducts from the New Hypoxia-Activated Prodrug CP-506 Using DNA Adductomics.
    Solivio MJ; Stornetta A; Gilissen J; Villalta PW; Deschoemaeker S; Heyerick A; Dubois L; Balbo S
    Chem Res Toxicol; 2022 Feb; 35(2):275-282. PubMed ID: 35050609
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.
    Stokes AM; Hart CP; Quarles CC
    Tomography; 2016 Sep; 2(3):229-237. PubMed ID: 27752544
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.
    Sun JD; Ahluwalia D; Liu Q; Li W; Wang Y; Meng F; Bhupathi D; Matteucci MD; Hart CP
    Am J Cancer Res; 2015; 5(7):2139-55. PubMed ID: 26328245
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    Cornillie J; Wozniak A; Pokreisz P; Casazza A; Vreys L; Wellens J; Vanleeuw U; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
    Mol Cancer Ther; 2017 Aug; 16(8):1566-1575. PubMed ID: 28566438
    [TBL] [Abstract][Full Text] [Related]  

  • 74. ONECUT2 is a driver of neuroendocrine prostate cancer.
    Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
    Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.
    Younger E; Ballman K; Lu Y; Pápai Z; Van Tine BA; Attia S; Schöffski P; Reinke D; Tap WD; Jones RL
    J Geriatr Oncol; 2020 Apr; 11(3):463-469. PubMed ID: 31126845
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    Reeves KM; Song PN; Angermeier A; Della Manna D; Li Y; Wang J; Yang ES; Sorace AG; Larimer BM
    Clin Cancer Res; 2022 Jan; 28(2):327-337. PubMed ID: 34615724
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
    Laubach JP; Liu CJ; Raje NS; Yee AJ; Armand P; Schlossman RL; Rosenblatt J; Hedlund J; Martin M; Reynolds C; Shain KH; Zackon I; Stampleman L; Henrick P; Rivotto B; Hornburg KTV; Dumke HJ; Chuma S; Savell A; Handisides DR; Kroll S; Anderson KC; Richardson PG; Ghobrial IM
    Clin Cancer Res; 2019 Jan; 25(2):478-486. PubMed ID: 30279233
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients.
    Kawaguchi K; Igarashi K; Kiyuna T; Miyake K; Miyake M; Murakami T; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Unno M; Eilber FC; Hoffman RM
    Cell Cycle; 2018; 17(5):627-633. PubMed ID: 29384032
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MRI-Based Deep Learning Segmentation and Radiomics of Sarcoma in Mice.
    Holbrook MD; Blocker SJ; Mowery YM; Badea A; Qi Y; Xu ES; Kirsch DG; Johnson GA; Badea CT
    Tomography; 2020 Mar; 6(1):23-33. PubMed ID: 32280747
    [TBL] [Abstract][Full Text] [Related]  

  • 80. DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts.
    Ellingsen C; Hompland T; Galappathi K; Mathiesen B; Rofstad EK
    Radiother Oncol; 2014 Feb; 110(2):335-41. PubMed ID: 24231244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.